hVIVO (LON:HVO) Trading Down 46.3% – Here’s What Happened

hVIVO plc (LON:HVO)’s stock price traded down 46.3% during mid-day trading on Saturday . The stock traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares traded hands during mid-day trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a “buy” rating on shares of hVIVO in a research note on Friday.

hVIVO Trading Down 46.3%

The company has a 50 day moving average of GBX 16.16 and a 200-day moving average of GBX 18.04. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97.

hVIVO (LON:HVO) last issued its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, research analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Activity

In other news, insider Yamin Mo’ Khan sold 3,062,246 shares of the stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). Company insiders own 14.03% of the company’s stock.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.